Who are the cancer survivors? A nationwide study in Denmark, 1943–2010

H B Hovaldt*,1,2, N P Suppli1, M H Olsen1, M Steding-Jessen3, D G Hansen4, H Møller5, C Johansen1,6 and S O Dalton1

1Danish Cancer Society Research Center, Unit of Survivorship, Strandboulevarden 49, DK-2100 Copenhagen Ø, Denmark; 2Department of Psychology, University of Copenhagen, Øster Farimagsgade 2a, DK-1353 Copenhagen K, Denmark; 3Danish Cancer Society, Documentation and Quality, Strandboulevarden 49, DK-2100 Copenhagen Ø, Denmark; 4National Research Center for Cancer Rehabilitation, Research Unit of General Practice, University of Southern Denmark, J.B. Winsløws Vej 9, Entrance B, 1st Floor, DK-5000 Odense C, Denmark; 5King’s College London, Section of Cancer Epidemiology and Population Health, Bermondsey Wing, 3rd Floor, Guy’s Hospital, Great Maze Pond, London SE1 9RT, UK and 6Department of Oncology, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen Ø, Denmark

Background: No nationwide studies on social position and prevalence of comorbidity among cancer survivors exist.

Methods: We performed a nationwide prevalence study defining persons diagnosed with cancer 1943–2010 and alive on the census date 1 January 2011 as cancer survivors. Comorbidity was compared by social position with the non-cancer population.

Results: Cancer survivors composed 4% of the Danish population. Somatic comorbidity was more likely among survivors (OR 1.59, 95% CI 1.57–1.60) and associated with higher age, male sex, short education, and living alone among survivors.

Conclusions: Among cancer survivors, comorbidity is common and highly associated with social position.

The number of cancer survivors is increasing in many countries (Engholm et al, 2010; Maddams et al, 2012; de Moor et al, 2013), mainly due to ageing populations and decreasing cancer mortality as a result of better diagnostics and treatment (Møller et al, 2002; Jemal et al, 2004; Australian Institute of Health and Welfare, Cancer Australia & Australasian Association of Cancer Registries, 2008; Rowland and Bellizzi, 2008; Parry et al, 2011). To our knowledge, no nationwide studies of social position and the prevalence of comorbidity have been performed among cancer survivors. Defining cancer survivors from date of diagnosis and throughout their lives (National Cancer Institute, 2014), we thoroughly characterised the national population of such survivors, compared the total burden of severe somatic comorbidity in cancer survivors and the non-cancer population, and described potential differences by social position among the cancer survivors.

MATERIAL AND METHODS

Study design and population. We performed a cross-sectional study of all people living in Denmark on 1 January 2011, who were identified in the civil registration system, comprising 5 560 628 people (Pedersen, 2011). Since 1943, all cases of cancer have been registered in the Danish Cancer Registry (Gjerstorff, 2011). We identified all persons diagnosed with cancer (excluding benign tumours, in situ cancers and non-melanoma skin cancers) in 1943–2010 and classified them according to their first (index) cancer. Somatic comorbidity measured by the Charlson Comorbidity Index (CCI) was calculated based on discharge information from 1978 (inpatient) and 1995 (outpatient) to census date from the National Patient Registry (Lynge et al, 2011) and information on all subsequent primary malignancies after the index cancer from the Danish Cancer Registry (Charlson et al, 1987; Dalton et al, 2008a). From the Danish Psychiatric Case Register (Mors et al, 2011), we defined severe psychiatric comorbidity as hospital contacts from 1969 (inpatient) or 1995 (outpatient) to the census date for schizophrenia and psychosis and affective disorders (Dalton et al, 2008a).

Education and cohabitation status was used as indicators for social position. Information was derived from the Integrated Database for Labour Market Research in Statistics Denmark (Thygesen, 1995) and the Danish Civil Registration System.

*Correspondence: HB Hovaldt; E-mail: habiho@cancer.dk or hanna.hovaldt@psy.ku.dk

Received 29 August 2014; revised 7 January 2015; accepted 27 January 2015; published online 26 February 2015

© 2015 Cancer Research UK. All rights reserved 0007 – 0920/15

www.bjcancer.com | DOI:10.1038/bjc.2015.68

1549
containing information on all Danish residents. Social position analyses were restricted to 30–90-year-olds, as information on education was not available for people born before 1920, and many Danes finish their education in the late twenties. Highest attained educational level was categorised as short (mandatory education, 7–9 years), medium, (high school or vocational education, 8–12 and 10–12 years of education for people born before and after 1958, respectively), and long education (>12 years, i.e., higher education). Cohabitation status was defined as cohabiting (married or cohabiting with partner), widow/widower, divorced, and single (not cohabiting and never married).

### Statistical analysis
The prevalence of cancer survivors was calculated from the number of people with a cancer diagnosis in the population on 1 January 2011. To analyse the risk for a CCI score ≥1 depending on being a cancer survivor, multivariate logistic regression analyses were performed with adjustment for sex, age, schizophrenia or psychosis, and affective disorders. The association between education and cohabitation status and somatic comorbidity was examined in 30–90-year-olds by multivariate logistic regression analyses stratified by cancer survivor or non-cancer population and time since diagnosis and adjusted for education, cohabitation status, sex, age, schizophrenia or psychosis, affective disorder, and cancer diagnosis (only in cancer survivors). Age was modelled as a second-order polynomial in all regression analyses.

### RESULTS
On 1 January 2011, 227704 cancer survivors were living in Denmark, corresponding to 4% of the total population. The median age of the cancer survivors was 67 years; 13% of 60–89-year-olds and 18% of >90-year-olds were cancer survivors (Table 1). Nearly 8% of cancer survivors had had more than one cancer (Table 2).

Median time since diagnosis was 6 years. Approximately one-third of people with cancers of the lung, esophagus, stomach, and pancreas had survived <1 year after diagnosis. One-third of survivors of female genital cancers had received their diagnosis ≥20 years before the census date, but only 4% of lung cancer survivors (Supplementary Information S1).

A CCI score ≥1 was found for 40% of the cancer survivors and for 16% of the non-cancer population, whereas prevalence of affective disorders and schizophrenia or psychosis was similar

### Table 1. Basic characteristics of 5560628 people living in Denmark on 1 January 2011

| Age on 1 January 2011 (years) | Cancer survivors | Non-cancer population |
|------------------------------|-------------------|------------------------|
| 0–29                         | 2%                | 3%                     |
| 30–59                        | 26%               | 52%                    |
| 60–89                        | 69%               | 59%                    |
| >90                          | 3%                | 1%                     |

| Charlson Comorbidity Index   | Cancer survivors | Non-cancer population |
|------------------------------|-------------------|------------------------|
| 0                            | 60%               | 40%                    |
| 1                            | 19%               | 11%                    |
| >2                           | 21%               | 4%                     |

| Schizophrenia or psychosis   | Cancer survivors | Non-cancer population |
|------------------------------|-------------------|------------------------|
| Ever diagnosed               | 1%                | 4%                     |
| Never diagnosed              | 99%               | 96%                    |

| Affective disorder           | Cancer survivors | Non-cancer population |
|------------------------------|-------------------|------------------------|
| Ever diagnosed               | 4%                | 6%                     |
| Never diagnosed              | 96%               | 94%                    |

| Education                    | Cancer survivors | Non-cancer population |
|------------------------------|-------------------|------------------------|
| Short                        | 26%               | 10%                    |
| Medium                       | 49%               | 6%                     |
| Long                         | 23%               | 5%                     |

| Cohabitation status          | Cancer survivors | Non-cancer population |
|------------------------------|-------------------|------------------------|
| Cohabiting                   | 65%               | 6%                     |
| Widow/widower                | 18%               | 15%                    |
| Divorcee                     | 11%               | 7%                     |
| Single                       | 7%                | 3%                     |

*The sum may exceed 100% due to rounding.
*Restricted to 30–90-year-olds.
*Excluding unknown education: 2% of cancer survivors, 3% of non-cancer population.
*Not cohabiting and never married.
*The proportion, who are cancer survivors of the total number of people in each category.
The proportion of survivors with a CCI score ≥ 1 ranged from 58% for lung cancer survivors to 29% for survivors of malignant melanoma. In comparison with the non-cancer population, the OR of all cancer survivors for having a CCI score ≥ 1 was 1.59 (95% CI 1.57–1.60) after adjustment for sex and age. Adjustments for psychiatric comorbidity did not change the estimate. Male sex and older age were associated with significantly increased odds for a CCI score ≥ 1 (data not shown).

Level of education and cohabitation status varied by cancer type, but cancer survivors with short education had the highest proportion of somatic and psychiatric comorbidity in all the age groups (Supplementary Information S2). Compared with survivors with higher education, those with short education had 57% higher odds for having a CCI score ≥ 1 (95% CI 1.53–1.62), and survivors with medium education had 33% higher odds (95% CI 1.29–1.36).

Living alone was also significantly associated with higher odds for a CCI score ≥ 1 in comparison with cohabiting; divorced people had the highest odds (OR 1.45, 95% CI 1.41–1.50) (Table 3). The social gradient in somatic comorbidity was slightly smaller among cancer survivors than the non-cancer population and tended to be smaller with time after diagnosis (Table 3).

### DISCUSSION

Cancer survivors have substantially higher odds for comorbid diseases in addition to their cancer than the cancer-free population. Short education and living alone were consistently associated with higher odds for comorbid diseases.

Our results confirm the prevalence of cancer type, age, sex and time since diagnosis found previously (Maddams et al, 2009; Siegel et al, 2012; Underwood et al, 2012; de Moor et al, 2013; Gatta et al, 2013; Jarlbæk et al, 2014); however, this is the first study to report results from a nationwide population with combined registry-based information on both cancer, demography, comorbidity, and social position.

Results from the National Health Interview Survey in the United States (n = 7292) indicated a higher prevalence of somatic comorbidity among both cancer survivors (57.7%) and matched controls (45.2%) than in our study; however, the survey data on comorbidity were self-reported in relation to functional limitations (Yabroff et al, 2004). We ensured consistent reporting of severe comorbid diseases leading to hospital contacts and found that cancer survivors had significantly greater odds for somatic comorbidity than the non-cancer population, which might be due to preexisting morbidity, late effects of cancer and cancer treatment, shared risk factors such as lifestyle, environmental exposure, and genetics, or joint effects of these (Aziz, 2007). Furthermore, the non-cancer illness of cancer survivors may not be

---

**Table 2.** Multivariate logistic regression analyses of the odds ratio (OR) with 95% confidence intervals (95% CIs) between somatic comorbidity (CCI ≥ 1), education, and cohabitation status among cancer survivors (n = 218 003) and the non-cancer population (n = 3 133 351) aged 30–90 years, living in Denmark on 1 January 2011, adjusted for sex and age

| Education | Non-cancer population, n = 3 133 351 | Cancer survivors, n = 218 003<sub><sup>a</sup></sub> | Cancer survivors <1 year after diagnosis, n = 23 958 | Cancer survivors 1–4 years after diagnosis, n = 47 262 | Cancer survivors 5–9 years after diagnosis, n = 47 577 | Cancer survivors 10–19 years after diagnosis, n = 47 539 | Cancer survivors ≥20 years after diagnosis, n = 31 667 |
|-----------|--------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| Short     | OR 1.77 95% CI 1.70–1.83 OR 1.74 95% CI 1.60–1.89 OR 1.64 95% CI 1.56–1.72 OR 1.63 95% CI 1.53–1.73 OR 1.49 95% CI 1.41–1.58 OR 1.40 95% CI 1.31–1.51 |
| Medium    | OR 1.34 95% CI 1.33–1.36 OR 1.39 95% CI 1.29–1.49 OR 1.35 95% CI 1.29–1.40 OR 1.34 95% CI 1.27–1.41 OR 1.31 95% CI 1.25–1.38 OR 1.24 95% CI 1.17–1.32 |
| Long      | OR 1.00 95% CI 1.00–1.00 OR 1.00 95% CI 1.00–1.00 OR 1.00 95% CI 1.00–1.00 OR 1.00 95% CI 1.00–1.00 OR 1.00 95% CI 1.00–1.00 OR 1.00 95% CI 1.00–1.00 |

**Abbreviation:** CCI = Charlson Comorbidity Index.

**Table 3.** Cancer-specific characteristics of 22 770 4 cancer survivors living in Denmark on 1 January 2011

| Index cancer type | Total, n = 227 704, %<sup>a</sup> | Men, n = 94 481, %<sup>a</sup> | Women, n = 133 223, %<sup>a</sup> |
|-------------------|----------------------------------|-------------------------------|-------------------------------|
| Mouth, pharynx and larynx | 2 4 1 | 1 2 1 |
| Esophagus, stomach and pancreas | 11 3 3 | 13 3 3 |
| Colon and rectum | 23 <1 39 | 23 <1 39 |
| Lung | 10 - 17 | 10 - 17 |
| Breast | 10 32 - | 10 32 - |
| Female genitalia | 10 - 17 | 10 - 17 |
| Male genitalia | 10 32 - | 10 32 - |
| Kidney and bladder | 10 14 4 | 10 14 4 |
| Malignant melanoma | 8 8 9 | 8 8 9 |
| Central nervous system | 6 6 6 | 6 6 6 |
| Leukemias, NHL and HL | 7 9 5 | 7 9 5 |
| Other cancers | 7 8 6 | 7 8 6 |

**Abbreviation:** CCI = Charlson Comorbidity Index.

<sup>a</sup>The sum may exceed 100% due to rounding.

<sup>b</sup>Excluding benign tumours, cancer in situ, and non-melanoma skin cancers.
managed optimally (Earle and Neville, 2004) contributing to the risk of hospitalisation for comorbidity.

Previous studies have shown that low social position is associated with higher cancer incidence for selected cancers and poorer survival after most cancers (Dalton et al, 2008b) and a higher risk for comorbid disease at the time of cancer diagnosis (Louwman et al, 2010). We show that the social gradient continues into life after cancer, a gradient that could not be explained by case-mix due to cancer type alone. We found that the social differences were smaller among those who had survived longer, which might be due to the social gradient in cancer survival (Dalton et al, 2008b), and because comorbidity is a strong predictor for early mortality from cancer (Yancik et al, 2001; Piccirillo et al, 2004).

The primary aim of this study was to characterise comorbidity and social position in a nationwide population of cancer survivors; however, information on individual lifestyle and behaviour could have provided further insight, as these are risk factors for both cancer and comorbid diseases. As the aim was to investigate the total burden of severe comorbidity, we included all comorbid diseases occurring before and after the index cancer. As secondary primary malignancies were included only for cancer survivors, comorbidity might be a late effect of cancer treatment and/or due to shared risk factors. Most comorbid conditions in people with recent cancers date from before the index cancer, while people with earlier cancers have comorbid conditions from after the index cancer. Finally, time since diagnosis was truncated, as primary malignancies were included only for cancer survivors, diseases occurring before and after the index cancer. Finally, time since diagnosis was truncated, as secondary malignancies were included only for cancer survivors, comorbidity might be a late effect of cancer treatment and/or due to shared risk factors. Most comorbid conditions in people with recent cancers date from before the index cancer, while people with earlier cancers have comorbid conditions from after the index cancer. Finally, time since diagnosis was truncated, as primary malignancies were included only for cancer survivors, diseases occurring before and after the index cancer. Finally, time since diagnosis was truncated, as primary malignancies were included only for cancer survivors, diseases occurring before and after the index cancer. Finally, time since diagnosis was truncated, as primary malignancies were included only for cancer survivors, diseases occurring before and after the index cancer.

This study, based on nationwide data, provides new insight into the total burden of severe comorbidity in the growing group of cancer survivors. Use of national registers prevents bias and provides consistent, complete, and valid individual-level information on social factors and morbidity, and the long tradition of systematic registration of cancer in Denmark ensures almost complete registration of cases.

CONCLUSION AND IMPLICATIONS

The population of Danish cancer survivors is large and some have survived for decades after their initial diagnosis. Beyond being impaired by the cancer treatment, cancer survivors are more affected by other chronic disorders than their non-cancer fellows, especially survivors with low social position. Further investigation of the causes of social differences in comorbidity are important to ensure equal access and optimal care and rehabilitation of both cancer and comorbid diseases for all cancer survivors.

ACKNOWLEDGEMENTS

This work was supported by the Danish Cancer Society.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

Australian Institute of Health and Welfare, Cancer Australia & Australasian Association of Cancer Registries (2008) Cancer Survival and Prevalence in Australia: Cancer diagnosed from 1982 to 2004. Australian Institute of Health and Welfare: Canberra, Australia, Cancer Series no. 42. Cat. No. CAN 38.

Aziz NM (2007) Cancer survivorship research: state of knowledge, challenges and opportunities. Acta Oncol 46: 417–432.

Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40: 373–383.

Dalton SO, Steding-Jessen M, Gislum M, Frederiksen K, Engholm G, Schuz J (2008a) Social inequality in incidence of and survival from cancer in a population-based study in Denmark, 1994-2003: Background, aims, material and methods. Eur J Cancer 44: 1938–1949.

Dalton SO, Schuz J, Engholm G, Johansen C, Kjaer SK, Steding-Jessen M, Storm HH, Olsen JH (2008b) Social inequality in incidence of and survival from cancer in a population-based study in Denmark, 1994-2003: summary of findings. Eur J Cancer 44: 2074–2085.

de Moor JS, Mariotto AB, Parry C, Alfano CM, Padgett L, Kent EE, Forsythe L, Scoppa S, Hachey M, Rowland JH (2013) Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev 22: 561–570.

Earle CC, Neville BA (2004) Under use of necessary care among cancer survivors. Cancer 101: 1712–1719.

Engholm G, Gislum M, Bray F, Hakulinen T (2010) Trends in survival of patients diagnosed with cancer in the Nordic countries 1964-2003 followed up to the end of 2006. Material and methods. Acta oncol 49: 545–560.

Gatta G, Mallone S, van der Zwan JM, Trama A, Siesling S, Capocaccia R (2013) Cancer prevalence estimates in Europe at the beginning of 2000. Ann Oncol 24: 1660–1666.

Gjerstorff ML (2011) The Danish Cancer Registry. Scand J Public Health 39: 42–45.

Jarlbæk L, Christensen L, Bruea E, Hansen DG (2014) The epidemiology of long- and short-term cancer survivors. A population-based cohort study exploring denominators for rehabilitation and palliative care programs. Acta oncol 53: 493–501.

Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jamison PM, Wingo PA, Howe HI, Anderson RN, Edwards BK (2004) Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 101: 3–27.

Louwman WJ, Aarts MJ, Houterman S, van Lenthe FJ, Coebergh JWW, Janssen-Heijnen MLG (2010) A 50% higher prevalence of life-shortening chronic conditions among cancer patients with low socioeconomic status. Br J Cancer 103: 1742–1748.

Lyenge S, Sandegard I, Reboli M (2011) The Danish National Patient Registry. Scand J Public Health 39: 30–33.

Maddams J, Brewster D, Gavin A, Steward J, Elliott J, Utey M, Moller H (2009) Cancer prevalence in the United Kingdom: estimates for 2008. Br J Cancer 101: 541–547.

Maddams J, Utey M, Moller H (2012) Projections of cancer prevalence in the United Kingdom, 2010-2040. Br J Cancer 107: 1195–1202.

Moller B, Fokjaer H, Hakulinen T, Tryggvadottir L, Storm HH, Talback M, Haldorsen T (2002) Prediction of cancer incidence in the Nordic countries up to the year 2010. Eur J Cancer Prev 11: S1–96.

Mors O, Perto GP, Mortensen PB (2011) The Danish Psychiatric Central Research Register. Scand J Public Health 39: 54–57.

National Cancer Institute (2014) Definitions: Survivorship definitions. Retrieved 8 July 2014, from http://cancercontrol.cancer.gov/ocs/statistics/definitions.htmls.

Parry C, Kent EE, Mariotto AB, Alfano CM, Rowland JH (2011) Cancer survivors: a booming population. Cancer Epidemiol Biomarkers Prev 20: 1996–2005.

Pedersen CB (2011) The Danish Civil Registration System. Scand J Public Health 39: 22–25.

Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel Jr EL (2004) Prognostic importance of comorbidity in a hospital-based cancer registry. Jama 291: 2441–2447.

Rowland JH, Bellizzi KM (2008) Cancer survivors and survivorship research: a reflection on today’s successes and tomorrow’s challenges. Hematol Oncol Clin North Am 22: 181–200.

Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62: 220–241.

Thygesen L (1995) The register-based system of demographic and social statistics in Denmark. Stat J UN Econ Comm Eur 12: 49–55.
Underwood JM, Townsend JS, Stewart SL, Buchanan N, Ekwueme DU, Hawkins NA, Li J, Peaker B, Pollack LA, Richards TB, Rim SH, Rohan EA, Sabatino SA, Smith JL, Tai E, Townsend G, White A, Fairley TL (2012) Surveillance of demographic characteristics and health behaviors among adult cancer survivors—behavioral risk factor surveillance system, United States, 2009. MMWR Surveill Summ 61: 1–23.

Yabroff KR, Lawrence WF, Clauser S, Davis WW, Brown ML (2004) Burden of illness in cancer survivors: findings from a population-based national sample. J Natl Cancer Inst 96: 1322–1330.

Yancik R, Wesley MN, Ries LAG, Havlík RJ, Edwards BK, Yates JW (2001) Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years or older. JAMA 285: 885–892.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.

Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)